Cui L, Deng JC, Zhang N. Recombinant human thrombopoietin in pediatric allogeneic hematopoietic stem cell transplantation: Clinical insights and future directions. World J Stem Cells 2025; 17(10): 112434 [DOI: 10.4252/wjsc.v17.i10.112434]
Corresponding Author of This Article
Nan Zhang, MD, PhD, Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, No. 288 Tianwen Avenue, Nan’an District, Chongqing 400010, China. zhangnan@hospital.cqmu.edu.cn
Research Domain of This Article
Hematology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Oct 26, 2025 (publication date) through Oct 27, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Stem Cells
ISSN
1948-0210
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Cui L, Deng JC, Zhang N. Recombinant human thrombopoietin in pediatric allogeneic hematopoietic stem cell transplantation: Clinical insights and future directions. World J Stem Cells 2025; 17(10): 112434 [DOI: 10.4252/wjsc.v17.i10.112434]
World J Stem Cells. Oct 26, 2025; 17(10): 112434 Published online Oct 26, 2025. doi: 10.4252/wjsc.v17.i10.112434
Recombinant human thrombopoietin in pediatric allogeneic hematopoietic stem cell transplantation: Clinical insights and future directions
Lu Cui, Jian-Chuan Deng, Nan Zhang
Lu Cui, Jian-Chuan Deng, Nan Zhang, Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
Co-corresponding authors: Jian-Chuan Deng and Nan Zhang.
Author contributions: Cui L collected and reviewed the literature, drafted the manuscript, and contributed to the data interpretation; Deng JC conceptualized the study, provided critical revisions to the manuscript, and supervised the overall project; Zhang N designed the study, critically reviewed the manuscript for important intellectual content, and provided supervision. Deng JC and Zhang N jointly supervised the work as co-corresponding authors. All authors read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nan Zhang, MD, PhD, Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, No. 288 Tianwen Avenue, Nan’an District, Chongqing 400010, China. zhangnan@hospital.cqmu.edu.cn
Received: July 28, 2025 Revised: September 2, 2025 Accepted: September 15, 2025 Published online: October 26, 2025 Processing time: 90 Days and 10.8 Hours
Abstract
The cohort study by Li et al provides timely and clinically relevant evidence on the use of recombinant human thrombopoietin (rhTPO) in pediatric allogeneic hematopoietic stem cell transplantation. The authors report enhanced platelet engraftment and a favorable safety profile, particularly in younger children aged 0-9 years. This age-dependent difference not only highlights the physiological responsiveness of early hematopoietic environments to rhTPO but also raises important questions about tailoring supportive therapies across pediatric age groups. While the findings are promising, the lack of a control group and single-center limitations warrant further multicenter, long-term investigations. Nevertheless, the study lays a compelling foundation for integrating rhTPO more broadly into pediatric transplant protocols and for advancing individualized post-transplant care.
Core Tip: This cohort study evaluates the safety and efficacy of recombinant human thrombopoietin (rhTPO) in pediatric allogeneic hematopoietic stem cell transplantation. The findings suggest that rhTPO promotes earlier platelet engraftment, particularly in younger children aged 0-9 years. This age-dependent response highlights the influence of developmental hematopoiesis on treatment outcomes. Despite the limitations of a single-center, non-randomized design, the study provides novel insights that support rhTPO as a promising supportive therapy in pediatric allogeneic hematopoietic stem cell transplantation and underscores the need for age-specific post-transplant strategies.
